BioNTech SE
BNTXNASDAQHealthcare● Active
$88.08
$-1.51(-1.69%)
Market Cap$22.3B
P/E Ratio—
52W High$124
52W Low$79.52
BioNTech SE (BNTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BNTX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.76B | $2.75B | $3.82B | $17.31B | $18.98B |
| Cost of Revenue | $0.62B | $0.54B | $0.60B | $3.00B | $2.91B |
| Gross Profit | $2.14B | $2.21B | $3.22B | $14.32B | $16.07B |
| Gross Margin %(computed) | 77.64% | 80.32% | 84.29% | 82.70% | 84.66% |
| Operating Expenses | |||||
| R&D Expenses | $2.02B | $2.25B | $1.78B | $1.54B | $0.95B |
| G&A Expenses | $0.59B | $0.53B | $0.49B | $0.48B | $0.28B |
| Total Operating Expenses | $2.76B | $3.52B | $2.53B | $1.67B | $0.78B |
| Operating Income | ($0.62B) | ($1.31B) | $0.69B | $12.64B | $15.28B |
| Operating Margin %(computed) | -22.63% | -47.77% | 18.08% | 73.03% | 80.54% |
| Interest Income | $0.25B | $0.00B | $0.35B | $0.05B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.01B | $0.02B | $0.01B |
| Income Before Tax | ($1.01B) | ($0.68B) | $1.19B | $12.95B | $15.05B |
| Income Tax Expense | $0.08B | ($0.01B) | $0.26B | $3.52B | $4.75B |
| Net Income | ($1.09B) | ($0.67B) | $0.93B | $9.43B | $10.29B |
| Net Margin %(computed) | -39.59% | -24.18% | 24.36% | 54.50% | 54.24% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-4.51 | $-2.77 | $3.87 | $38.08 | $43.87 |
| Wtd Avg Shares | 0.24B | 0.24B | 0.24B | 0.24B | 0.24B |
| EBITDA | ($0.26B) | ($0.37B) | $1.38B | $13.10B | $15.00B |
| EBITDA Margin %(computed) | -9.29% | -13.34% | 36.07% | 75.65% | 79.06% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · EUR · B
Explore more BioNTech SE data
About BioNTech SE (BNTX) Income Statement
BioNTech SE (BNTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BNTX reported revenue of $2.76B, gross profit of $2.14B (gross margin 77.64%), and net income of ($1.09B) — a net profit margin of -39.59%.
Frequently asked questions
BNTX · 4 questionsBioNTech SE (BNTX) reported revenue of $2.76B for 2025, up 0.2% year-over-year.
BNTX revenueBNTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08